Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of V116 in Pneumococcal Vaccine-Experienced Adults ≥50 Years
jRCT2071220025Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (3 arms), sponsored by Merck & Co. Started Aug 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on jRCT2071220025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220025.